Skip to main content
Premium Trial:

Request an Annual Quote

Celera Stock Sale Nets $983 M to Fund Product, Technology Development

Premium

R

OCKVILLE, Md.--Celera Genomics received $983.25 million from the March 3 sale of 4.37 million shares of its stock, the Washington Post reported. The net proceeds from the offering are intended primarily to fund Celera’s new product and technology development activities in functional genomics, with an emphasis on proteomics and personalized health/medicine. Proceeds might also be used for acquisitions, alliances, or collaborations.

Filed under

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.